Cerus דיבידנד 2024

מה עושה Cerus?

Cerus Corporation is a biotechnology company specialized in the development and marketing of products for the processing and transfusion of blood products. The company was founded in 1991 and is headquartered in Concord, California. Cerus Corporation is listed on the NASDAQ stock exchange and employs approximately 450 employees worldwide. The history of Cerus Corporation began when its founder, Stephen Isaacs, received a blood transfusion and subsequently became infected with the Hepatitis B virus. This incident inspired him to start a company focusing on the development of technologies for the safe transfusion of blood products. In 1993, Cerus Corporation introduced its first product, the Intercept Blood System. This system utilized ultraviolet light and chemicals to deactivate pathogens such as viruses, bacteria, and parasites in blood. The business model of Cerus Corporation revolves around the development and distribution of products for medical needs. The company's focus is on the processing of blood products such as platelets, plasma, and red blood cells to reduce the risk of infectious diseases and other potentially harmful side effects in blood transfusions. Cerus also provides training and technical support for its products. Cerus Corporation has several divisions, including the Intercept Blood System, Blood Center Technology, and Innovative Technology. The Intercept Blood System division is the largest and most popular, offering products such as the Intercept Blood System for platelets and plasma, the Intercept Blood System for red blood cells, the Intercept Blood System for PAS (reduced volume blood bank) and the Intercept Blood System for Fresh Frozen Plasma. Cerus Corporation's Blood Center Technology division provides technologies and devices for blood banks and transfusion services, including transfusion safety systems and blood testing devices. The Innovative Technology division specializes in the development of new technologies and products. Another product of Cerus Corporation is INTERCEPT FDA Approved Plasma, which was approved by the US Food and Drug Administration (FDA) in 2018. The plasma is made from donated blood and processed using the INTERCEPT technology. The INTERCEPT technology decontaminates various blood components, increasing their safety in transfusions. Cerus Corporation has achieved significant success in the medical technology industry. Cerus Corporation's Intercept Blood System is approved in more than 25 countries and has helped save countless lives and prevent diseases for healthcare professionals and patients. The company has been recognized multiple times for its innovative products and services, including receiving the Gold Medal at the Edison Awards in 2017 and the Technology Pioneer Award from the World Economic Forum in 2016. In summary, Cerus Corporation is a successful biotechnology company that develops and distributes innovative technologies for the processing and transfusion of blood products. Through its technology and products, Cerus contributes to increasing the safety of blood transfusions by reducing the risk of infectious diseases and other potentially dangerous side effects. Cerus Corporation will continue to play an important role in the medical technology industry in the future. Cerus הוא אחד החברות הפופולאריות ביותר על Eulerpool.com.